IVVD Quote, Financials, Valuation and Earnings

Amneal Pharmaceuticals has a net margin of -653.11% compared to Invivyd's net margin of -4.26%. Invivyd's return on equity of -- beat Amneal Pharmaceuticals's return on equity of -587.3%.

Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Amneal Pharmaceuticals has an analysts' consensus of $11.50 which suggests that it could grow by 33.41%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amneal Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.898%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Amneal Pharmaceuticals pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $9.3M, which are smaller than Amneal Pharmaceuticals quarterly revenues of $730.5M. Invivyd's net income of -$60.7M is lower than Amneal Pharmaceuticals's net income of -$31.1M. Notably, Invivyd's price-to-earnings ratio is -- while Amneal Pharmaceuticals's PE ratio is 101.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 0.96x for Amneal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PepGen has a net margin of -653.11% compared to Invivyd's net margin of --. Invivyd's return on equity of -- beat PepGen's return on equity of --.

Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand PepGen has an analysts' consensus of $12.20 which suggests that it could grow by 419.15%. Given that Invivyd has higher upside potential than PepGen, analysts believe Invivyd is more attractive than PepGen.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $9.3M, which are larger than PepGen quarterly revenues of --. Invivyd's net income of -$60.7M is lower than PepGen's net income of -$22.2M. Notably, Invivyd's price-to-earnings ratio is -- while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -653.11% compared to Invivyd's net margin of 2.31%. Invivyd's return on equity of -- beat Pfizer's return on equity of 8.91%.

Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Invivyd has higher upside potential than Pfizer, analysts believe Invivyd is more attractive than Pfizer.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Invivyd pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Invivyd quarterly revenues are $9.3M, which are smaller than Pfizer quarterly revenues of $17.8B. Invivyd's net income of -$60.7M is lower than Pfizer's net income of $410M. Notably, Invivyd's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -653.11% compared to Invivyd's net margin of 3.02%. Invivyd's return on equity of -- beat Entrada Therapeutics's return on equity of 18.3%.

Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Entrada Therapeutics has an analysts' consensus of $25.43 which suggests that it could grow by 135.22%. Given that Invivyd has higher upside potential than Entrada Therapeutics, analysts believe Invivyd is more attractive than Entrada Therapeutics.

Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Invivyd quarterly revenues are $9.3M, which are smaller than Entrada Therapeutics quarterly revenues of $37.4M. Invivyd's net income of -$60.7M is lower than Entrada Therapeutics's net income of $1.1M. Notably, Invivyd's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 5.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 1.98x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.